Company news

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news

Syndax Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 24, 2023: Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute…

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news

Press releases — page 3

Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023

Syndax Announces Participation at the Citi 18th Annual BioPharma Conference

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

Syndax Announces Participation at Upcoming Investor Conferences

Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference

Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Proposed $150 million Public Offering of Common Stock

Syndax Announces Pricing of $150 Million Public Offering of Common Stock

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference

Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022

Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer

Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day

Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update

Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022

Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer

Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia

Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Syndax Announces Proposed Public Offering of Common Stock

Syndax Announces Pricing of $75.3 Million Public Offering

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab

Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update

Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021